What we do Q-Line Biotech Limited develops, manufactures, and markets diagnostic reagents, kits, POC devices, and equipment primarily for clinical diagnostics sectors. |
Founded in 2,010 |
Market share Emerging player in India's IVD industry focusing on clinical chemistry, hematology, immunodiagnostics, and molecular diagnostics. |
Problem solved Provides reliable diagnostic consumables and equipment to improve healthcare diagnostics accuracy and accessibility. |
Top clients or who we serve Diagnostic service providers, hospitals, medical colleges; primarily B2B. |
Key management - |
Our journey and innovations Started in 2010, first manufacturing plant in 2016, expanded into diagnostics labs and radiology services, regular regulatory approvals since 2021. |
Where we operate Primarily India with regulatory audits by Indian and European agencies. |
Top products or what we offer Diagnostic reagents, kits, POC devices across clinical chemistry, hematology, immunodiagnostics, molecular diagnostics. |
Top brands - |
Raw materials needed - |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue driven by ongoing sales of diagnostic consumables and equipment, moderately recurring. |
Our industry position Growing presence in Indian IVD diagnostics with expansion plans via manufacturing and radiology services. |
Financial highlights Fiscal 2025 revenue Rs 314 crore; net profit Rs 28 crore indicating strong growth and profitability. |
Geographical revenue split Revenue primarily from Indian market. |
Order book - |
Whats driving growth Increasing healthcare diagnostics demand, regulatory approvals, product range expansion, and facility acquisitions. |
Our future plans IPO in 2025, expand manufacturing capacity with new Lucknow plant, focus on core IVD business growth. |
Our green promise - |
Our people and values - |
Key challenges ahead Competitive IVD market, regulatory compliance, and maintaining growth momentum post-IPO. |
Interesting facts Regulatory certified by CDSCO and European bodies; diversified into radiology services recently. |
Risks and strategy Mitigate regulatory and market competition risks through quality focus, product innovation, and strategic divestments. |
